JP2017517506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517506A5 JP2017517506A5 JP2016568497A JP2016568497A JP2017517506A5 JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5 JP 2016568497 A JP2016568497 A JP 2016568497A JP 2016568497 A JP2016568497 A JP 2016568497A JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 102000009410 Chemokine receptor Human genes 0.000 claims 3
- 108050000299 Chemokine receptor Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000037844 advanced solid tumor Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037843 metastatic solid tumor Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001534P | 2014-05-21 | 2014-05-21 | |
| US62/001,534 | 2014-05-21 | ||
| PCT/US2015/031081 WO2015179236A1 (en) | 2014-05-21 | 2015-05-15 | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517506A JP2017517506A (ja) | 2017-06-29 |
| JP2017517506A5 true JP2017517506A5 (enExample) | 2018-07-12 |
Family
ID=53284562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568497A Pending JP2017517506A (ja) | 2014-05-21 | 2015-05-15 | 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10023649B2 (enExample) |
| EP (1) | EP3145956A1 (enExample) |
| JP (1) | JP2017517506A (enExample) |
| KR (1) | KR20170004006A (enExample) |
| CN (1) | CN106413751A (enExample) |
| AU (1) | AU2015264528A1 (enExample) |
| BR (1) | BR112016026993A2 (enExample) |
| CA (1) | CA2949214A1 (enExample) |
| IL (1) | IL248540A0 (enExample) |
| MX (1) | MX2016015181A (enExample) |
| RU (1) | RU2016146993A (enExample) |
| WO (1) | WO2015179236A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105979961B (zh) * | 2014-02-05 | 2020-12-18 | 西达-赛奈医疗中心 | 用于治疗癌症和感染性疾病的方法和组合物 |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| CA2955184A1 (en) * | 2016-01-25 | 2017-07-25 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist for treating cancer |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CA3082255A1 (en) * | 2016-11-23 | 2020-06-10 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| US10174122B2 (en) | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| JP6501171B2 (ja) | 2017-03-29 | 2019-04-17 | 塩野義製薬株式会社 | 癌治療用医薬組成物 |
| CA3061959A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer |
| CN111278858B (zh) | 2017-07-11 | 2024-07-23 | 指南针制药有限责任公司 | 结合人cd137的激动剂抗体及其用途 |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| TWI838350B (zh) | 2017-11-06 | 2024-04-11 | 美商瑞佩特治療公司 | 抗癌劑 |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019109238A1 (en) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| US20210363266A1 (en) * | 2018-01-22 | 2021-11-25 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof |
| CN111683961A (zh) * | 2018-03-13 | 2020-09-18 | 豪夫迈·罗氏有限公司 | 4-1bb激动剂与抗cd20抗体的治疗剂组合 |
| WO2019196868A1 (en) * | 2018-04-10 | 2019-10-17 | Wuxi Biologics (Shanghai) Co., Ltd. | A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| CA3137373A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2020231809A1 (en) | 2019-05-10 | 2020-11-19 | Lyvgen Biopharma Co., Ltd. | Humanized anti-cd137 antibodies and uses thereof |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| BR112022012821A2 (pt) * | 2020-01-13 | 2022-12-13 | Cytodyn Inc | Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5 |
| US20230087164A1 (en) * | 2020-02-04 | 2023-03-23 | Genmab A/S | Antibodies for use in therapy |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| JP2023545444A (ja) * | 2020-10-13 | 2023-10-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 膵管腺癌を処置するための併用免疫療法および組成物 |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2022261018A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| JP2024527606A (ja) | 2021-07-14 | 2024-07-25 | ジェネンテック， インコーポレイテッド | 抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体及び使用方法 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN1214043C (zh) | 1998-12-01 | 2005-08-10 | 蛋白质设计实验室股份有限公司 | 抗γ－干扰素的人化抗体 |
| CN1296960A (zh) * | 1999-11-22 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸 |
| JP4052515B2 (ja) | 2001-08-31 | 2008-02-27 | 協和醗酵工業株式会社 | ヒト型ｃｄｒ移植抗体およびその抗体断片 |
| NZ538216A (en) * | 2002-07-15 | 2008-09-26 | Mayo Foundation | Treatment and prophylaxis with 4-1BB-binding agents |
| CA2548454C (en) | 2003-12-04 | 2013-12-31 | Kyowa Hakko Kogyo Co., Ltd. | Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| US20060153808A1 (en) | 2004-11-17 | 2006-07-13 | Board Of Regents, The Universtiy Of Texas System | Cancer immunotherapy incorporating p53 |
| WO2006088447A1 (en) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| CA2610661A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| SI2614082T1 (sl) | 2010-09-09 | 2018-12-31 | Pfizer Inc. | Molekule, ki vežejo 4-1BB |
| SG191716A1 (en) | 2010-11-19 | 2013-08-30 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
-
2015
- 2015-05-15 EP EP15727159.4A patent/EP3145956A1/en not_active Withdrawn
- 2015-05-15 MX MX2016015181A patent/MX2016015181A/es unknown
- 2015-05-15 JP JP2016568497A patent/JP2017517506A/ja active Pending
- 2015-05-15 CA CA2949214A patent/CA2949214A1/en not_active Abandoned
- 2015-05-15 US US15/312,515 patent/US10023649B2/en not_active Expired - Fee Related
- 2015-05-15 AU AU2015264528A patent/AU2015264528A1/en not_active Abandoned
- 2015-05-15 BR BR112016026993A patent/BR112016026993A2/pt not_active Application Discontinuation
- 2015-05-15 WO PCT/US2015/031081 patent/WO2015179236A1/en not_active Ceased
- 2015-05-15 CN CN201580027437.7A patent/CN106413751A/zh active Pending
- 2015-05-15 KR KR1020167035347A patent/KR20170004006A/ko not_active Withdrawn
- 2015-05-15 RU RU2016146993A patent/RU2016146993A/ru not_active Application Discontinuation
-
2016
- 2016-10-27 IL IL248540A patent/IL248540A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017517506A5 (enExample) | ||
| Suurs et al. | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2017516775A5 (enExample) | ||
| MX2025002661A (es) | Composiciones anti-cd24 y usos de las mismas | |
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| JP2017048208A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| BRPI0918178A8 (pt) | anticorpos monoclonais para tratamento de câncer | |
| JP2019527706A5 (enExample) | ||
| JP2015214582A5 (enExample) | ||
| JP2017505782A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2017530950A5 (enExample) | ||
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| Lin et al. | Combination treatment including targeted therapy for advanced hepatocellular carcinoma | |
| JP2016510028A5 (enExample) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований |